DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
Authors
Keywords
-
Journal
Pharmaceutics
Volume 11, Issue 5, Pages 199
Publisher
MDPI AG
Online
2019-05-02
DOI
10.3390/pharmaceutics11050199
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines : mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx
- (2018) Marie-Anne Loriot et al. BULLETIN DU CANCER
- Therapeutic Drug Monitoring in Oncology: IATDMCT Recommendations for 5-Fluorouracil Therapy
- (2018) Jan H. Beumer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features
- (2018) Carolina Palmela et al. Gut and Liver
- A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
- (2018) Chi C. Tong et al. Frontiers in Oncology
- Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers
- (2018) Carin A.T.C. Lunenburg et al. EUROPEAN JOURNAL OF CANCER
- A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy
- (2018) Linda M. Henricks et al. EUROPEAN JOURNAL OF CANCER
- Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD *2A variant: A matched pair analysis
- (2018) Linda M. Henricks et al. INTERNATIONAL JOURNAL OF CANCER
- DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
- (2018) Linda M Henricks et al. LANCET ONCOLOGY
- Primary sclerosing cholangitis – a comprehensive review
- (2017) Tom H. Karlsen et al. JOURNAL OF HEPATOLOGY
- A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis
- (2017) Sun Young Kim et al. Radiation Oncology
- Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach
- (2017) Michele Boisdron-Celle et al. SEMINARS IN ONCOLOGY
- Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies
- (2017) Han-Xiang Zhan et al. Cancer Medicine
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene
- (2016) André B.P. van Kuilenburg et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers
- (2016) Bart A. W. Jacobs et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Therapeutic drug monitoring of 5-fluorouracil
- (2016) James J. Lee et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity – Ready for clinical practice?
- (2016) Didier Meulendijks et al. CANCER TREATMENT REVIEWS
- Upfront Genotyping ofDPYD*2Ato Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
- (2016) Maarten J. Deenen et al. JOURNAL OF CLINICAL ONCOLOGY
- Development and validation of a rapid and sensitive UPLC–MS/MS method for determination of uracil and dihydrouracil in human plasma
- (2016) Bart A.W. Jacobs et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
- (2016) Mustafa Suker et al. LANCET ONCOLOGY
- Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients
- (2016) Adam M. Lee et al. Pharmacogenetics and Genomics
- Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis
- (2016) Luo Fang et al. Scientific Reports
- DPYDGenotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer
- (2016) Valérie Boige et al. JAMA Oncology
- Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat
- (2015) Giulia Bonato et al. DIGESTIVE DISEASES
- Clinical validity of aDPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines
- (2015) Giuseppe Toffoli et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
- (2015) Didier Meulendijks et al. LANCET ONCOLOGY
- Genetic Polymorphisms of Dihydropyrimidinase in a Japanese Patient with Capecitabine-Induced Toxicity
- (2015) Masahiro Hiratsuka et al. PLoS One
- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity
- (2014) S. M. Offer et al. CANCER RESEARCH
- Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer
- (2014) Daniel A. Goldstein et al. Clinical Colorectal Cancer
- Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis
- (2014) Dan Rosmarin et al. JOURNAL OF CLINICAL ONCOLOGY
- Liver injury possibly related to drug interaction after liver transplant: a case report
- (2014) L. Q. Zhu et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)
- (2014) Adam M. Lee et al. JNCI-Journal of the National Cancer Institute
- A Community-Based Multicenter Trial of Pharmacokinetically Guided 5-Fluorouracil Dosing for Personalized Colorectal Cancer Therapy
- (2014) J. N. Patel et al. ONCOLOGIST
- Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio
- (2014) Johanna Sistonen et al. PHARMACOGENOMICS
- Hepatocellular carcinoma review: Current treatment, and evidence-based medicine
- (2014) Ali Raza WORLD JOURNAL OF GASTROENTEROLOGY
- Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer
- (2013) Kyung-Hun Lee et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity
- (2013) S. M. Offer et al. CANCER RESEARCH
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
- (2013) K E Caudle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Value of Dihydrouracil/Uracil Plasma Ratios in Predicting 5-Fluorouracil-Related Toxicity in Colorectal Cancer Patients
- (2013) MH Kristensen et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes
- (2013) Frédéric Peyrade et al. ORAL ONCOLOGY
- DPYDIVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis
- (2013) Salvatore Terrazzino et al. PHARMACOGENOMICS
- LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients
- (2012) Barbara Büchel et al. BIOMEDICAL CHROMATOGRAPHY
- Validation of an Ultra-High Performance Liquid Chromatography Tandem Mass Spectrometric Method for Quantifying Uracil and 5,6-Dihydrouracil in Human Plasma
- (2012) François Coudoré et al. JOURNAL OF CHROMATOGRAPHIC SCIENCE
- Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6
- (2012) R. R. Kaldate et al. ONCOLOGIST
- Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency
- (2011) Maurice C. van Staveren et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
- (2011) M. J. Deenen et al. CLINICAL CANCER RESEARCH
- Pharmacogenetics: From Bench to Byte— An Update of Guidelines
- (2011) J J Swen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study
- (2011) Qing Zhang et al. INVESTIGATIONAL NEW DRUGS
- Safety of capecitabine: a review
- (2010) Sameh E Mikhail et al. Expert Opinion On Drug Safety
- Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients
- (2010) Romain Coriat et al. INVESTIGATIONAL NEW DRUGS
- Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial
- (2009) Michael S. Braun et al. JOURNAL OF CLINICAL ONCOLOGY
- Graft rejection occurring in post-liver transplant patients receiving cytotoxic chemotherapy: A case series
- (2009) Hui-Hui Tan et al. LIVER TRANSPLANTATION
- Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment
- (2009) Ursula Amstutz et al. PHARMACOGENOMICS
- HPLC with UV or Mass Spectrometric Detection for Quantifying Endogenous Uracil and Dihydrouracil in Human Plasma
- (2008) R. Svobaite et al. CLINICAL CHEMISTRY
- Incidence and Management of Colorectal Cancer in Liver Transplant Recipients
- (2008) Taiga Nishihori et al. Clinical Colorectal Cancer
- Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer
- (2008) Erick Gamelin et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group
- (2008) Matthias Schwab et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started